Compare Cipla with Fresenius Kabi Onco. - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CIPLA vs FRESENIUS KABI ONCO. - Comparison Results

CIPLA     Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

FRESENIUS KABI ONCO. 
   Change

Fresenius Kabi Oncology is the erstwhile Dabur Pharma, which was incorporated in March 2003. The company is a leading player in oncology in India and the international markets. Fresenius Kabi Oncology operates in the regulated markets namely the US a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    CIPLA FRESENIUS KABI ONCO. CIPLA/
FRESENIUS KABI ONCO.
 
P/E (TTM) x 36.9 22.1 166.7% View Chart
P/BV x 4.3 3.1 137.5% View Chart
Dividend Yield % 0.5 0.0 -  

Financials

 CIPLA   FRESENIUS KABI ONCO.
EQUITY SHARE DATA
    CIPLA
Mar-20
FRESENIUS KABI ONCO.
Mar-13
CIPLA/
FRESENIUS KABI ONCO.
5-Yr Chart
Click to enlarge
High Rs586176 332.7%   
Low Rs35779 454.5%   
Sales per share (Unadj.) Rs207.037.7 549.4%  
Earnings per share (Unadj.) Rs18.65.1 365.1%  
Cash flow per share (Unadj.) Rs33.26.7 493.3%  
Dividends per share (Unadj.) Rs4.000-  
Dividend yield (eoy) %0.80-  
Book value per share (Unadj.) Rs195.542.5 459.5%  
Shares outstanding (eoy) m806.35158.23 509.6%   
Bonus/Rights/Conversions ESOS--  
Price / Sales ratio x2.33.4 67.4%   
Avg P/E ratio x25.325.0 101.4%  
P/CF ratio (eoy) x14.218.9 75.1%  
Price / Book Value ratio x2.43.0 80.6%  
Dividend payout %21.50-   
Avg Mkt Cap Rs m379,91220,135 1,886.8%   
No. of employees `00025.81.2 2,243.5%   
Total wages/salary Rs m30,270703 4,304.6%   
Avg. sales/employee Rs Th6,459.65,176.2 124.8%   
Avg. wages/employee Rs Th1,171.2610.4 191.9%   
Avg. net profit/employee Rs Th580.2699.6 82.9%   
INCOME DATA
Net Sales Rs m166,9495,963 2,799.7%  
Other income Rs m3,44218 19,122.2%   
Total revenues Rs m170,3915,981 2,848.9%   
Gross profit Rs m32,0601,430 2,241.8%  
Depreciation Rs m11,747258 4,554.7%   
Interest Rs m1,974-26 -7,590.8%   
Profit before tax Rs m21,7821,216 1,791.0%   
Minority Interest Rs m-4750-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-68 0.0%   
Tax Rs m6,312342 1,844.5%   
Profit after tax Rs m14,995806 1,860.7%  
Gross profit margin %19.224.0 80.1%  
Effective tax rate %29.028.1 103.0%   
Net profit margin %9.013.5 66.5%  
BALANCE SHEET DATA
Current assets Rs m117,0385,102 2,294.2%   
Current liabilities Rs m43,9312,385 1,841.7%   
Net working cap to sales %43.845.6 96.1%  
Current ratio x2.72.1 124.6%  
Inventory Days Days96150 63.8%  
Debtors Days Days85113 75.1%  
Net fixed assets Rs m107,4245,148 2,086.7%   
Share capital Rs m1,613158 1,019.3%   
"Free" reserves Rs m156,0186,556 2,379.9%   
Net worth Rs m157,6306,732 2,341.6%   
Long term debt Rs m23,693952 2,488.2%   
Total assets Rs m236,62610,388 2,277.9%  
Interest coverage x12.0-45.8 -26.3%   
Debt to equity ratio x0.20.1 106.3%  
Sales to assets ratio x0.70.6 122.9%   
Return on assets %7.27.5 95.5%  
Return on equity %9.512.0 79.5%  
Return on capital %12.814.6 87.9%  
Exports to sales %33.074.5 44.4%   
Imports to sales %024.8 0.0%   
Exports (fob) Rs m55,1754,441 1,242.5%   
Imports (cif) Rs mNA1,477 0.0%   
Fx inflow Rs m56,0365,298 1,057.8%   
Fx outflow Rs m6,7641,772 381.7%   
Net fx Rs m49,2723,525 1,397.6%   
CASH FLOW
From Operations Rs m30,6851,274 2,408.3%  
From Investments Rs m1,040-1,204 -86.4%  
From Financial Activity Rs m-29,488-196 15,037.3%  
Net Cashflow Rs m2,340-126 -1,852.9%  

Share Holding

Indian Promoters % 16.0 0.0 -  
Foreign collaborators % 20.8 81.0 25.7%  
Indian inst/Mut Fund % 12.2 0.3 4,066.7%  
FIIs % 23.7 9.6 246.9%  
ADR/GDR % 1.1 0.0 -  
Free float % 26.2 9.1 287.9%  
Shareholders   161,166 42,599 378.3%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare CIPLA With:   FDC  UNICHEM LAB  PROCTER & GAMBLE HEALTH  AJANTA PHARMA  ALEMBIC  

Compare CIPLA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Tanks 531 Points; Reliance Industries & IndusInd Bank Fall 5%(Closing)

Indian share markets witnessed huge selling pressure today and failed to hold on to their opening gains as profit booking and weakness across all sectors erased gains.

Related Views on News

CIPLA Share Price Up by 5%; BSE HEALTHCARE Index Up 1.2% (Market Updates)

Jan 25, 2021 | Updated on Jan 25, 2021

CIPLA share price is trading up by 5% and its current market price is Rs 850. The BSE HEALTHCARE is up by 1.2%. The top gainers in the BSE HEALTHCARE Index are CIPLA (up 5.0%) and AUROBINDO PHARMA (up 9.6%). The top losers are NATCO PHARMA (down 0.2%) and PIRAMAL ENTERPRISES (down 0.6%).

CIPLA 2019-20 Annual Report Analysis (Annual Result Update)

Nov 4, 2020 | Updated on Nov 4, 2020

Here's an analysis of the annual report of CIPLA for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of CIPLA. Also includes updates on the valuation of CIPLA.

CIPLA Announces Quarterly Results (1QFY21); Net Profit Up 21.4% (Quarterly Result Update)

Aug 10, 2020 | Updated on Aug 10, 2020

For the quarter ended June 2020, CIPLA has posted a net profit of Rs 6 bn (up 21.4% YoY). Sales on the other hand came in at Rs 43 bn (up 7.2% YoY). Read on for a complete analysis of CIPLA's quarterly results.

CIPLA Announces Quarterly Results (4QFY20); Net Profit Down 35.1% (Quarterly Result Update)

May 19, 2020 | Updated on May 19, 2020

For the quarter ended March 2020, CIPLA has posted a net profit of Rs 2 bn (down 35.1% YoY). Sales on the other hand came in at Rs 44 bn (down 0.6% YoY). Read on for a complete analysis of CIPLA's quarterly results.

CIPLA Announces Quarterly Results (3QFY20); Net Profit Up 9.4% (Quarterly Result Update)

Feb 6, 2020 | Updated on Feb 6, 2020

For the quarter ended December 2019, CIPLA has posted a net profit of Rs 4 bn (up 9.4% YoY). Sales on the other hand came in at Rs 44 bn (up 9.1% YoY). Read on for a complete analysis of CIPLA's quarterly results.

More Views on News

Most Popular

Time to Book Profits in Pharma Stocks(Fast Profits Daily)

Jan 15, 2021

In this video, I'll show you why it might be the right time to take money of the table in pharma stocks.

Smallcap Stocks: Your Best Bet for 2021 and Beyond(Profit Hunter)

Jan 15, 2021

The pandemic failed to thwart Richa's investing success formula for 2020.

Buzzing Sectors Before Budget 2021(Fast Profits Daily)

Jan 12, 2021

The budget is just a few weeks away. Which stocks can you expect to move? Find out in this video.

Here's Why Smallcaps Could Be Your Best Investment in 2021(Profit Hunter)

Jan 12, 2021

Select smallcaps hold a great potential to become the multibaggers of tomorrow. Here's how you could get in early into these stocks.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

CIPLA SHARE PRICE


Jan 25, 2021 (Close)

TRACK CIPLA

COMPARE CIPLA WITH

MARKET STATS